RE:RE:"Nearing 90 patient interim enrollment"I have noted over time that option season (and new share issues) are accompanied by very large cries and bashing from the usual suspects to help justify the share price suppression seen daily at these times. Curious though how one can be the chief shareholder activist while getting info on trial progression from insiders to quote here. Must be some new age thing? Or just an inadvertant slip?
I used a 10X EBITDA multiple and only 50% of the EBITDA at 40% mkt penetration. I fully expect to hear I'm light - the $5 could easily be $8 to $10 if conservatism was removed and more of a market multiple was used.
Out of curiosity what would the BS EBITDA multiple have to be to generate a share price above zero but no higher than $0.315? Several hangers on are trying very hard to sell that.
Based on the 179 plus 52 already achieved ("exceeding expectations") what do you think someone like Baxter would pay if it was concluded to sell at this very moment? I would expect it to be substantially above $0.315 a share. Much closer to the $5 I would think.